Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc.) on August 31, 2020. The registrant is a Delaware corporation with its principal executive offices in Cambridge, Massachusetts, and its common stock trades on The Nasdaq Global Market under the symbol MGTA. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Executive Departure: Jason Ryan, the Chief Operating and Financial Officer (and principal financial and accounting officer), informed the Company on August 31, 2020, that he will resign effective October 1, 2020.
- Reason for Departure: The resignation is for personal reasons and is not related to any disagreements with the Company regarding operations, policies, financial disclosures, accounting, or legal matters.
- Succession Plan: The Company has commenced a formal search for a new chief financial officer.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks, contingencies, or unusual items are disclosed in this report other than the standard disclosure of the officer's departure.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Confirm the interim arrangement for the principal financial and accounting officer role between October 1, 2020, and the appointment of a successor.
- Review subsequent filings for any updates on the search for a new CFO.